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1. Introduction 
Trypanosomiases and  leishmaniases are protozoan parasitic 
infections of humans and some domestic animals in four 
continents
1-3
.  Human African trypanosomiasis (HAT) is caused 
by protozoa of the genus Trypanosoma transmitted to humans by 
the bite of infected tsetse fly (genus Glossina), of which two 
morphologically indistinguishable subspecies  exist,  that  differ 
in their clinical presentation and epidemiology.  T. brucei 
gambiense  the slower developing chronic form of HAT, causes 
95% of all cases and is prevalent in West and Central Africa.  T. 
brucei rhodesiense  causes the acute more virulent form of the 
disease prevalent in East and Central Africa; it has a higher 
mortality rate due to its rapid progression
4
 and  poor early 
diagnosis.
5
   Leishmaniases like trypanosomiasis is a disease 
found in Asia, South America, and East Africa caused by  
L.donovani, transmitted into the host by the bite of infected 
phlebotomine sandflies
2
 and manifests itself in three different 
forms-visceral (kala-azar) the most serious form of the disease, 
cutaneous (the most common), and mucocutaneous.  American 
trypanosomiasis (Chagas disease is caused by T.cruzi) is a 
potentially life-threatening disease confined to the region of the 
Americas primarily Latin America and is transmitted to humans 
by contact with the faeces or urine of the triatomine bug
3
.  
Chemotherapy of trypanosomiasis and leishmaniasis is 
inadequate as many treatments have poor clinical efficacy, with 
patients suffering side effects or are toxic at the high dosage 
regimes, used especially in the late chronic stages. This situation 
has been further aggravated by the emergence of resistance to 
some of the first line drugs,
6
 or the increasing incidence of 
treatment failure
7
.  Genetic approaches have identified some key 
gene products  responsible for resistance
8
 in trypanosomes these 
include the  trypanosome P2 adenosine transporter, AT1
9
,  
responsible for the uptake of the front-line drugs melarsoprol and 
pentamidine used to treat HAT, which was found to be mutated 
or absent in a number of  drug resistant strains
10
 . The 
upregulation of the melarsoprol-trypanothione (Mel-T) 
transporter, multidrug resistance protein A (MRPA) 
11
, which 
caused resistance by the rapid efflux of melarsoprol from the cell 
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and  the loss of  the amino acid transporter, AAT6 in resistant 
strains
12
, involved in the uptake of the drug eflornithine used to 
treat  HAT.    In T. cruzi  the  down regulation of the 
trypanosome nitroreductase (NTR) 
13
, an activator of the front-
line pro-drugs nifurtimox and benznidazole used to treat Chagas 
disease,  may lead to resistance.  These concerns has highlighted 
the need for a new generation of drugs.   
 Focused drug discovery over the past two decades has 
concentrated on the identification and characterization of 
different biochemical and molecular targets leading to the 
identification of some pathways common to all pathogenic 
trypanosomatids,
14
 opening the possibility for the development of 
clinically useful drugs active against all these parasites.   
Amongst these is the synthesis of glutathione (GSH), polyamines 
and trypanothione, essential for the survival of T. brucei 
14
 and 
related trypanosomatids. The trypanothione cycle maintains the 
hexapeptide, trypanothione (N
1
, N
8
-bis (glutathionyl)spermidine) 
(T(SH)2), an antioxidant replacing  glutathione (GSH) via 
trypanothione reductase (TR), in its reduced form  and so 
decreases the cell's sensitivity  to oxidative stress; which is a 
consequence of  rapid growth.
7
  A variety of trypanothione 
reductase inhibitors have been reported to date of both natural 
and synthetic origin which include peptides, polyamines,
15,16
 
tricyclics,
17
 2-aminodiphenyl sulfides,
18
 2- and 3-substituted 1,4-
naphthoquinone derivatives as subversive substrates
19
  and 
organometallic compounds.
20
   Only a few compounds achieve 
activities in the nanomolar range (100 nM) required to overcome 
the induced phenotypic changes in TR and a 90% level of 
inhibition.   However, the development of time-dependent 
irreversible TR inhibitors based on benzofuranyl 3,5-bis-
polyamine
21
 and spermidine derivatives of the alkaloid 
lunarine,
22,23  
overcome the drawback of competitive inhibitors of 
TR. 
Using a lead directed approach to identify potential 
antiprotozoal compounds we previously reported N-
benzyloxycarbonyl-S-(2,4-dinitrophenyl)glutathione diesters  
with in vitro inhibitory activity  against the parasitic growth of 
Trypanosoma and Leishmania  parasites.
24
  Initially these 
compounds were thought to exert their effect by inhibition of 
enzymes of the trypanothione cycle due to the similarity of these 
compounds to trypanothione as they both contained a glutathione 
peptide backbone.  This inference was dismissed, based on an 
absence of any inhibitory effects of these compounds on enzymes 
of the trypanothione cycle
25
 (trypanothione reductase, 
tryparedoxin (TXN1 and TXN2) and glutathione peroxidase).  A 
study of the inhibitory properties of  lipophilic 
benzyloxycarbonyl-S-(2,4-dinitrophenyl) glutathione diesters 
derivatives against T.b.brucei and T.b.rhodesiense, found a 
parabolic dependence between log(1/ED50) and log P 
(lipophilicity)  with both species showing an optimium value in 
the range between 5.0-6.0, which indicated membrane 
penetration,  played a key role in the antiparasitic activity of 
these compounds
26, 27
.  A QSAR analysis of  the inhibition data 
determined a, linear relationship between  log P and the Taft’s 
steric parameter (s)
26,27 
the latter related to lipophilic chain 
branching.  Microscopy studies showed that exposure of the 
parasite to the glutathione diester derivatives, caused 
morphological changes to the parasitic cytoskeleton resembling 
the type of  changes seen with antiprotozoal membrane binding 
peptides responsible for pore formation in trypanosomes,
28,29
 
suggesting that  these peptides might facilitate cell death by a 
similar process.
25 
 Studies on glutathione diester peptides, such as 
13, with a range of model membranes in Langmuir trough studies 
confirmed these peptides  form stable monolayers
19
 and undergo 
aggregation and re-orientation of the membrane so altering 
fluidity, surface relaxation and elasticity.  The reduced surface 
flexibility of the protozoan membrane was suggested to be 
related to the parasitic killing property of these compounds
30
  and 
membrane integrity.   
Apart from disruption of the parasitic membrane integrity, 
other studies indicate that these peptides at M levels exerted an 
inhibitory effect on efflux via the trypanosome multidrug 
resistance protein (MRPA), a putative thiol conjugate 
transporter,
25,31
 indicating an intracellular target for the action of 
these compounds.  The MRPA protein plays an important role in 
the development of drug resistance
 11,32
 and is a member of the 
ATP binding cassette (ABC) transporter superfamily in 
mammalian systems, proposed to act with the glutathione 
transferases (GST) to remove endogenous electrophiles and 
exogenous compounds from the cytosol and reduce intracellular 
toxicity and oxidative stress.
33
 To progress our work, aimed at 
understanding and improving the antiprotozoal killing power of 
S-(2,4-dinitrophenyl)glutathione dibutyl diesters in vitro whilst 
minimizing host toxicity we prepared a series of N-substituted 
derivatives, 2-20, as shown in Scheme 1.   
 
Scheme 1. Chemical structures of N-blocked-S-2,4-
dinitrophenylglutathione di-butyl esters tested for antiparasitic 
activity. 
A study of the in vitro activity of these compounds against 
T.b.rhodesiense has been used to ascertain the effect changes 
made at the N-site have on the activity of these peptides.  HPLC 
studies with optical microscopy have been used to further 
elaborate the mechanism and specificity of action of these 
compounds with the view to improve their anti-trypanosomal 
activity.   
2. Results & Discussion 
2.1. Chemical synthesis 
     The compounds used in this study were prepared  either by 
procedure A or B using compounds 1 or 2 respectively as starting 
materials, as shown in Scheme 2 and were obtained in reasonable 
yield (in parenthesis) with the exception   of  20, that was 
obtained in low yield  <30%.   The method used was dependent 
on the availability of the S-blocked glutathione diacid.  In the 
case  of compounds  11 -13 and 19  the availability of the S-
blocked glutathione diacid
34
   resulted in the use of Method A, N-
acylation followed by  the SOCl2 esterification of the compound 
in BuOH to the diester.  Compounds 3-10, 15-18 and 20 were 
synthesized by the dimethylaminopyridine (DMAP)
 34
  catalysed 
  
N-acylation or N-arylation  of compound 2 as shown in Method 
B.  Compound 14  was prepared by the reaction   of  N,N-bis[2-
oxo-3-oxazolidinyl]phosphinic chloride (BOP-Cl) with  indole 
propionic acid and compound 2 by a  variation of Method B.  
Compound 2  was obtained as an oil, by the esterification of S-
2,4-dinitrophenylglutathione 1, in BuOH/HCl(g) and used 
without further purification in the above studies.   Analytically 
pure compound 2 was obtained by the N-deprotection of 
compound 16 using TFA/CH2Cl2.  The use of either SOCl2/BuOH 
or BuOH/HCl(g) in esterification was based on the  
regioselectivity  of these reagents with glutathione derivatives.
34
  
 
Scheme 2.  General synthetic route to N-blocked -S-2,4-dinitro 
phenylglutathione di-butyl esters. 
 
2.2. Screening against  T. b. rhodesiense, L. donovani & 
T.cruzi. 
The N-substituted glutathione diesters investigated in this study 
were based on S-(2,4-dinitrophenyl)glutathione (GSDNP; 1), 
modified  by N-acylation/N-arylation of the amino group with 
different alkyl and aryl substituents of varying size and volume 
3-8, 15-17, aryl or aryl/alkyl substituents  9-13, tricyclo 
substituent  18, and heterocyclic substituents 14 and 20.  The N-
substituted glutathione derivatives were then converted to the 
corresponding dibutyl esters by thionyl chloride esterification in 
butan-1-ol.  Compound 8 was prepared because of the 
importance of  N-myristoylation    to the survival of T.b.brucei 
35
   
in post-transitional modification, membrane targeting and the 
biological activity of many important proteins. Compound 20 the 
N-(4-amino-6-chloro-1,3,5-triazin-2-yl)-S-(2,4-dinitrophenyl) 
glutathione di-n-butyl ester  derivative isolated instead of the 
desired compound, N-(2,4-diamino-1,3,5-triazin-2-yl)-S-(2,4-
dinitrophenyl) glutathione di-n-butyl ester derivative, to act as a   
substrate of the  P2  purine transporter.
9
 Variation of  N-
substituents on the S-(2,4-dinitrophenyl)glutathione dibutyl ester 
scaffold 2-20 (Scheme 1) produced some changes in the 
inhibitory effects of these compounds against T.b.rhodesiense 
(>1M).  Using the inhibitory activity of compound 2(1.88 M), 
with an unsubstituted nitrogen as a reference, the N-substituents 
on compounds 4=11>17>3>8 were found to weaken the 
inhibitory properties of these peptides against T.b.rhodesiense 
whilst for 16<12<14<13<18<9<10=15<5=19<7<6<2 they 
enhanced activity.  Of the N-substituents the t-Boc group 16 was 
found to be the most active glutathione diester derivative(see 
Table 1) with an ED50 value of  0.22 M; 8.5 fold more active 
than 2(see Table 1) with compounds  12-14 being the most active 
N-aryl/alkyl substituents.  As previously observed glutathione 
compounds with a log P of 4.0-7.0 showed the highest in vitro 
activity against Trypanosoma.
26,27
  Compound 8 containing the 
N-myristoyl group(log P: 8.73) proved no exception and showed 
significantly reduced  activity versus 2.  Compound 20, although 
similar to the substrates of the P2 receptor showed no enhanced 
activity  in the inhibition of trypanosome growth.  An effect of 
the variation of groups on the N-site was on the cytotoxicity of 
these compounds, measured using KB cells as a standard 
cytotoxicity index and cited in many texts,
36,37,38
 which were 
lower in comparison to the unmodified compound 2 especially in 
the case of compound 3-5, 8-11 and 17-20.  
Table 1. The biological properties of glutathione derivatives 
against T. b. rhodesiense
d
, L.donovani
e
 & T.cruzi
f
. 
a 
Calculated using  xlogP 60 
b
 Human oral pharyngeal carcinoma; 72h assay; 3 replication expts.  
c
 NA: not active. 
d
 Pentamidine isethionate control (ED50, 0.33 nM); 72h assay; 3 replication 
expts.  
e  
Sodium stibogluconate (NaSb
v
) control. ED50 33ugSb
V
ml; 120h assay; 3 
replication expts. 
f
 Benznidazole control. ED50 4.4uM; 72h assay; 3 replication expts.  
g
 G=RTlnKi(Ki ED50 the ratio(Ki:Cpd ID/ Ki: 2) 
t   toxic to macrophages; t/+  toxic to macrophage + parasite 
 
The relative toxicity expressed as the ratio of the inhibition of 
KB cells/ T. b. rhodesiense, was highest for compounds 5, 9, 10, 
18 and 19 where the ratio was >400.  Of the compounds tested 
only compound 2 was observed visually by optical microscopy to 
be toxic (t) to the macrophage host at a concentration of 30M, 
as evidenced by lysis of the cell membrane (see Table 1).  The 
toxicity of compound 2 may be due to its amphiphilic nature 
allowing it to function as a cationic surfactant, disrupting the cell 
membrane of the macrophage.  Compounds 16, 12-14 showed 
enhanced parasitic inhibition against T. b. rhodesiense that can be 
related to the interaction of the compound with the parasitic 
membrane.  Assuming that the anti-parasitic activity (ED50) 
observed is primarily related to binding (Ki) of the compounds 
with the parasitic membrane then we can calculate an interaction 
  
energy for binding  at 25 o C, using G=RTlnKi(Ki ED50 
the ratio(Ki:Cpd ID/ Ki: 2)) (see Table 1).  For compounds 5-7, 
9-10, 12-16, 18-19 this agrees with the interaction of  N-
substituents with the parasitic cell membrane via weak 
hydrophobic forces i.e. London and van der Waals forces (<1-
15.0 kcal mol
-1
) to enhance binding.   
      Compounds 16 & 18 in addition to showing  good parasitic 
activity against T.b.rhodesiense, also showed appreciable activity 
against  L.donovani  both at ~10M and  T.cruzi of 16.5 and 4.5 
M respectively.  Compound 18, appears to be an interesting 
compound with broad spectrum antiparasitic activity against   
T.b.rhodesiense, L.donovani and T.cruzi and a possible candidate 
for further development. 
   
2.3 QSAR analysis of data. 
 
      QSAR analysis, of the ED50
 
results against T. b. rhodesiense, 
were undertaken using the CODESSA Pro program
39
 to 
determine an inhibition model.  Satisfactory multi-linear 
regression models were obtained using the structural descriptors 
calculated solely using the program.  Of the compounds in Table 
1, only the 18 related compounds 2-20 were used in the data set 
to generate an initial two descriptor multi-linear regression 
QSAR model with R
2
=0.59 and F=11.7.  The data set of 
compounds was then reduced to improve the statistics of this 
model, by the stepwise removal of outliers 16, 15, 3, 5 and 18 in 
the order given, to obtain equation 1.  Further reduction of the 
data set did not significantly improve the statistics of the two 
descriptor QSAR model identified, relating  Log ED50 negatively 
to the average number of carbon atoms, NC and  SZX, the ZX 
shadow  the maximum molecular size of the compound in the ZX 
plane, equation 1. 
 
Log ED50 = – 35.5 NC + 0.045 SZX + 5.85       (1) 
N=14, R2 = 0.90,  F=49.7, s2= 0.046 
 
The correlation between the predicted and observed log ED50 
using equation 1 is shown in Fig. 1.   
Figure 1. The correlation between calculated and experimental, 
log ED50  values using  the two descriptor model (1). 
The QSAR model,  equation 1, contains a constitutional 
descriptor, the average number of carbon atoms, NC   that 
dominates the equation based on its coefficient size and is  
possibly related to saturation and the  hydrophobic character of 
the  compound and its negative association  in the equation, a 
reflection of its solubility in solution/ membrane.
40
   The 
geometrical descriptor, SZX, the ZX shadow  is  positive  and  
based on its smaller coefficient,  weakly  opposes this character 
and is related to the  maximum molecular size and orientation of  
the compound  in the ZX plane.
41
  The model was used to predict 
an  ED50 value of 7.8 M for N-(2,4-diamino-1,3,5-triazia-2-yl)-
S-(2,4-dinitrophenyl)glutathione di-n-butyl ester that eluded 
preparation and resulted in the isolation of  compound 20.     
Outliers 16, 15, 5 and 18 occurred in a cluster above the 
correlation determined by equation 1, indicating that the model 
underestimated their ED50 values  to that  determined 
experimentally.   Compounds 16, 15, 5 and 18 share a common 
feature that the substituent present contains either a secondary 
(iso-propyl or t- butyl) substituent suggesting that the NC 
descriptor underestimates the hydrophobicity of branched carbon 
compounds.  The membrane binding properties of these type of 
compounds have been confirmed by LB-trough studies on model 
membranes that indicated they formed stable monolayers in 
aqueous solutions with  the orientation of the peptide at the 
air/water interface in the ZX/ZY plane and its 
orientation/molecular conformation  being modulated  by the 
specific composition of the lipids forming the monolayer.
31
   In  
neat membranes composed of phospholipids and dioctadecyl-
dimethylammonium bromide (DODAB),  N-blocked-S-2,4-
dinitrophenylglutathione diesters adopt a confirmation in the 
ZX/ZY plane with the peptide carbonyl group backbone parallel 
to the air-water interface
31
 and peptide backbone perpendicular to 
the air –water interface (Scheme 3A).  However in monolayers 
made of sphingomyelin-cholesterol that resemble raft membrane 
structures, the peptide  conformation was found to be preserved 
to that observed in the aqueous phase, with the C=O group of the 
peptide backbone being perpendicular to the air-water interface 
(Scheme 3B).  This radical change in conformation adversely 
affects the proportion of peptide spanning the membrane/aqueous 
solution interface that relates to binding and helps explain the 
specificity of  these types of compounds.    
 
Scheme 3. A model of the molecular  orientation of the peptide 
in (A) monolayer made with phospholipids with two aliphatic  
  
chains (B) sphingomyelin-cholesterol monolayer .  The relative 
sizes of molecules are only illustrative and out-of-scale. 
Raft like structures have been proposed to be specifically 
enriched in the flagellar membrane of T.b.brucei 
42
 and play an 
important role in both sequestering and organizing specialized  
protein complexes,  some related to the transport functions of the 
parasite and its viability  to  scavenge metabolites.  
 
2.4. HPLC and optical microscopy studies 
HPLC and optical microscopy  was used to ascertain  the location 
and fate of the T. b. brucei   inhibitor, N-benzyloxycarbonyl-S-
(4-bromobenzyl)glutathione dimethyl ester.  N-Benzyloxy 
carbonyl-S-(4-bromobenzyl)glutathione dimethyl ester, although 
not  the most  inhibitory derivative identified against  T. b. 
brucei, ( 40% (30 M )) was chosen for use in  the study as the 
higher concentrations used aided its detection  by absorbance, 
using  HPLC-UV.  Exposure of N-benzyloxycarbonyl-S-(4-
bromobenzyl) glutathione dimethyl ester (50 M) with T.b.brucei 
on examination by  optical microscopy showed changes in the 
parasitic cytoskeleton,  firstly with  immobility of the parasite 
after 1 min,  swelling of the  parasite head after 5 min and a 
circular appearance after 30-40 mins, in which the particles 
inside the cell showed a high degree of swirling motion similar 
that seen with H2O2 propelled nanomotors ,
43
  that  slowed down 
after cell death and  lysis, after an hour (see Fig. 2).  
 
Figure 2. Morphological changes observed for T. b. brucei on 
exposure to N-benzyloxycarbonyl-S-(4-bromobenzyl)glutathione 
dimethyl ester (50 M) by microscopy (magnification x 1000) 
and the recording of images at different times. (a) 1 min (b) 5 
min (c) 20 min (d) 30 min.  
The time-dependent decrease of the extracellular concentration of 
N-benzyloxycarbonyl-S-(4-bromobenzyl)glutathione dimethyl 
ester over 120 mins  is not reflected in the observed intracellular 
change in the concentration of the diester (Fig. 3) which is 
maximal after 5 mins, indicating that extracellular adsorption is 
not responsible for the intracellular concentration of  the 
compound but an alternative active mechanism of uptake.  
 
Figure 3. HPLC-UV analysis of extracellular and intracellular 
concentrations of N-benzyloxycarbonyl-S-(4-bromobenzyl) 
glutathione dimethyl ester in T. b. brucei cells incubated with 50 
M of the drug (HMI-9/10 %) at 37 
o
C.  Error bars represent 
standard deviations for triplicate determinations. 
The fate of the compound in the parasitic membrane was 
ascertained by treatment of pelleted cells with 1M NaCl or 6M 
urea and HPLC-UV analysis of the released compound in 
comparison with standards.  The treatment of membranes with 
1M NaCl led to the release of N-benzyloxycarbonyl-S-(4-
bromobenzyl) glutathione diester  and monoester from the 
membrane in the % ratio 76:24 into solution confirming the 
diesters susceptibility to hydrolysis. The corresponding 6M urea 
treated sample led to the release of N-benzyloxycarbonyl-S-(4-
bromobenzyl) glutathione diester, monoester and diacid from the 
membrane  into solution  in the % ratio 80: 8: 12 indicating the 
diacid to be tightly associated with the membrane.   
Discussion 
The results of the present study provide the basis for a QSAR 
model, with good statistical significance, to describe the 
inhibitory activity of  N-substituted glutathione diester based 
anti-trypanosomal compounds.  Previous QSAR studies on 
diester derivatives of these peptides proposed a model that bears 
some similarities to equation 1, where log (1/ED50) was related 
negatively to log P and positively to Es, the degree of branching 
and indirectly to molecular size.  In that study a model was 
proposed in which these compounds inserted into the membrane 
of T. b. brucei cells via weak lipophilic forces, compromising   
structural and membrane fluidity.
26
  The studies reported here 
further support that view, with the N-substituents of glutathione 
contributing to a small increase in lipophilic binding energy of 
1.2-5.3   kJ mol
-1 
 (0.29-1.26 kcal mol
-1
).  Model membrane 
studies indicated that the confirmation of the peptide is preserved 
to that in the aqueous phase in raft membrane structures (Scheme 
3B), which is specifically enriched in the flagellar membrane of 
T.b.brucei 
42
.  The anti-trypanosomal inhibitory property of 
glutathione derivatives appear to be related to lipophilicity and 
molecular size/orientation of the peptide which is related to 
binding/affinity of the compound and the composition of the 
membrane.  The bloodstream form  trypomastigote is covered in 
a dense protective coat of variant surface glycoproteins, VSGs 
(variant surface glycoproteins)
44
.  The flagellar pocket,
45
 located 
at the base of the flagellum occupies 2-3% of the total plasma 
membrane and is the only gap in the parasites defenses where 
nutrient uptake by receptor mediated endocytosis (RME) and 
secretion by exocytosis occurs and is enriched with raft like 
membrane structures.  Microscopy and HPLC uptake studies on  
exposure of the compound to bloodstream stage T. b. brucei cells 
suggests that intracellular uptake of the inhibitor occurs quickly 
via  an active transport process that results in the observed  
immobilization of the parasite within 1 min of exposure to the 
compound.  Nutrient uptake via binding to the flagellar pocket, is 
the most likely process to explain the rapid intracellular uptake of 
the compound, after 5 mins (Fig 3).  The rate of endocytosis in 
Trypanosoma brucei  is equivalent to the internalization of the 
entire flagellar pocket membrane every 1-2 minutes
46
,  the same 
time frame observed for the immobilization of the parasite and 
the maximal intracellular concentration of compound.    
Endocytosis has  been recently demonstrated as a bona fide drug 
target,
47
 in the African trypanosome, Trypanosoma brucei, it is 
intimately involved in maintaining homeostasis of the cell 
surface proteome, morphology of the flagellar pocket and in 
  
vitro,  its shutdown is associated with rapid cell death, as in this 
study (Fig. 2).  The effect of intracellular uptake of glutathione 
diesters by endocytosis  probably results in the  inhibition of the 
MRPA efflux pump and/or TST (trypanothione transferase) 
protein, the former 
 
identified as
  
an inhibitory target of these 
compounds based on the inhibition of a strain of  T.b.brucei 247 
over-expressing the TbMRPA protein by 50-100x fold
25
.  Both 
proteins  acts in synergy and are responsible for the removal of 
endogenous electrophiles and exogenous compounds from the 
cytosol which otherwise would cause toxicity and cell death by 
creating oxidative stress.32  Ezatiostat hydrochloride (TLK199; -
glutamyl-S-(benzyl)cysteinyl -R(-)-phenyl glycine diethyl ester) 
a glutathione analog diester prodrug is also an inhibitor of the 
multidrug resistance associated protein-1 (MRP-1)
48
 and its de-
esterified product  -glutamyl-S-(benzyl)cysteinyl - R(-)-phenyl 
glycine (TLK117) both an inhibitor of both the MRP-1 protein  
and glutathione transferase (GST) enzymes(see Scheme 4).
48,49
   
Scheme 4. Structures of TLK199 and TLK117, inhibitors of the 
multidrug resistance protein, (MRP-1). 
The slow decrease in the extracellular concentration of the 
compound over 120 mins (see Fig. 3) is a result of its insertion into 
the membrane bilayer via hydrophobic adsorption compromising 
cytoskeleton integrity.  However as cell death occurs after 30 mins, 
see Fig 2 this suggests that it is not the major process and 
endocytosis is the only process consistent with the observed  
intracellular concentration of the compound, the cell’s rapid 
immobilization  and the short time scale for cell death.   P-
glycoprotein (P-gp/ABCB1), is the model cell membrane ABC 
transporter 
50,51
 
  
where high P-gp inhibitory potency has been 
associated with high lipophilicity and an interaction with the 
transporter via the membrane bilayer.
52,53 
  
The direct exposure of the compound to motile L. donovani,  
extracellular promastigote stage parasites, in vitro, showed no  
inhibitory activity  over a 2h  period indicating  that  active uptake 
of the peptide did not occur due to differences in feeding between 
the extracellular promastigote and amastigote stages of these 
different parasites.  The major difference in the role of the flagellar 
pocket/membrane of the extracellular form of T.b.brucei with L. 
donovani is its importance for parasitic survival due to its 
restrictive metabolic capability which renders it dependent on 
salvage pathways and receptor mediated scavenging of metabolites 
from the host via the flagellar pocket membrane.  T.b. brucei 
requires inosine monophosphate (IMP), cholesterol, lipoproteins, 
serum components and lipids 
56
 from the host to multiply.  The 
methodology for L. donovani and T. cruzi assays are similar, using 
murine peritoneal macrophages as host cells.  However, 
Leishmania amastigotes reside in a parasitophorous vacuole within 
the cell 
54
  and this is reflected in the  5-day assay as the antimonial 
control requires a longer period to reach the intracellular, intra-
vacuale amastigote whereas T. cruzi amastigotes are in the 
cytoplasm
55 
and so only require a three day period  for the 
benznidazole control to be effective. The longer time taken for 
drugs to reach the intracellular amastigote in the case of L. 
donovani and T. cruzi assays may result in the hydrolysis products 
of the diesters, the monoester and diacid  being the inhibitor of  the  
amastigote stage of these parasites. 
In conclusion, an understanding of the therapeutic and toxic effects 
of lipophilic glutathione diesters and their ability to target the 
flagellar pocket/membrane of T. b. brucei will aid selectivity and 
the further development of new compounds for HAT 
chemotherapy. 
 
4. Experimental 
4.1.  Chemistry 
4.1.1. General 
Precursors and solvents were purchased commercially and 
purified appropriately. GSH, DMAP, CbzCl, 3-phenylpropionyl 
chloride, tert-butylacetyl chloride and 4-methylvaleric acid were 
obtained from the Avocado Chemical Co. Ltd (UK).  
Indolepropionic acid, isobutyryl chloride and phenylacetyl 
chloride from Lancaster (UK).   Di-tert-butyl dicarbonate, 1-
adamantyl fluoroformate, phenoxyacetyl chloride, 
trimethylacetyl chloride, 2, 5-dimethoxytetrahydrofuran (DMT) 
and N,N-bis[2-oxo-3oxazolidinyl] phosphonic chloride (BOP-
Cl) were obtained from the Aldrich Chemical Co. Ltd. (UK). 
Glutathione derivative, N-(benzyloxycarbonyl)-S-(4-
bromobenzyl)glutathione dimethyl ester was provided by 
D’Silva et al.
34
 Analytical thin-layer chromatography was 
performed on Merck silica gel 60F
254 
aluminium backed TLC 
plates and were visualized by fluorescence quenching under UV 
light or I2 staining.  Preparative thin-layer chromatography 
(PTLC) was performed on Analtech silica gel GF 2000 microns 
and were visualized by fluorescence quenching under UV light.  
Melting points were determined on an Electrothermal apparatus 
and are  reported uncorrected   
1
H NMR spectra were recorded 
on a Joel 270 MHz FT-NMR spectrometer, and chemical shifts 
are reported in parts per million downfield with reference to 
tetramethysilane.   Mass spectra were recorded by B. Stein at the 
EPSRC Mass Spectrometry service centre, Swansea for EI and 
CI(NH3) spectra, on a VG quarto II triple quadropole mass 
spectrometer   and accurate mass  Liquid Secondary Ion Mass 
Spectrometry (LSIMS) measurements on a Finnigan MAT 900 
XLT using a  Cs+ ions to ionize.  Elemental analysis was 
performed at the Micro Analytical Service, Manchester  Univ, 
UK.   
4.1.2.  N-Blocked-S-(2,4-dinitrophenyl)glutathione di-n-butyl 
ester derivatives 
The preparation of the compounds of this series is illustrated in 
Scheme 1 by the general methods reported below:   
Method A : S-(2,4-Dinitrophenyl)glutathione (1) was dissolved 
in MeOH and then Et3N (3eq), required acyl halide (1.5-2eq) and 
dimethylaminopyridine (0.05eq). The reaction mixture was 
stirred overnight at RT, evaporated, acidified to pH 2 with dilute 
HCl (10%) and the organic layer was then extracted with AcOEt. 
After drying with MgSO4, filtration and evaporation, the residue 
was re-suspended in n-butanol and thionyl chloride (2.2eq) was 
added dropwise. The solution was left stirring overnight at RT 
and then evaporated. The residue was usually retriturated with 
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Et2O and the solid refrigerated, filtered under vacuo and purified 
by preparative chromatography if required. 
Method B : Et3N (1.1 eq), required acyl halide (1.1eq) and 
dimethylaminopyridine (0.05eq) were added to a solution of S-
(2,4-dinitrophenyl)glutathione di-n-butyl ester (2) in MeOH. The 
reaction mixture was stirred overnight at RT, evaporated and the 
organic layer was then extracted with AcOEt. After drying with 
with Et2O and the solid refrigerated, filtered under vacuo and 
purified by preparative chromatography if required.  
4.1.2.1. S-(2,4-Dinitrophenyl)glutathione (1) was prepared 
according according to Sokolovsky et al 
57
. 
4.1.2.2. S-(2,4-Dinitrophenyl)glutathione di-n-butyl ester (2) 
was prepared by N-deprotection of 16 with  trifluoroacetic acid 
(2eq) in CH2Cl2. The reaction mixture was left stirring for 18hrs 
at RT. The solvent was then removed under vacuo and the 
organic layer extracted with AcOEt. The aqueous phase was then 
neutralised with NaOH (10%) and the organic layer extracted 
with CHCl3. The latter organic layer was then washed with brine 
and dried with MgSO4. After filtration and evaporation of the 
solvent, the residue was triturated with Et2O. Purification by 
PTLC (CHCl3/MeOH : 9/1) gave the product as yellow crystals.  
Yield 50%; mp 98-100C; 
1
H NMR (D6MSO)  9.0 (s, 1H), 8.8 
(m, 1H),  8.6 (t, J= 9.5 Hz, 2H), 8.1 (d, J= 9.5 Hz,  1H), 4.8 (m, 
1H), 4.1-3.9 (m, 5H), 3.95 (m, 2H), 3.6 (m, 2H), 2.3 (t, J= 7.8 
Hz, 2H), 2.0 (m, 2H), 1.6 (m, 4H), 1.4 (m, 4H), 1.0 (t, J= 7.0 Hz, 
6H).   Ir (cm
-1
) v     3289 (NH),  2958 (CH), 1640 (C=O),  1529   
(NO2).  Anal. Calcd for C24H35N5O10S, 1.3H2O: C, 47.27; H, 
6.12; N, 11.5. Found: C, 46.98; H, 5.98; N, 11.77. 
4.1.2.3. N-(Acetyl)-S-(2,4-dinitrophenyl)glutathione di-n-
butyl ester (3)  was prepared according to Method B using  
acetic anhydride.  Purification by PTLC (CHCl3/MeOH : 19/1) 
gave the product as a yellow crystals.  Yield 45%; mp 140-
142C; 
1
H NMR (D6MSO)  8.95 (s, 1H ), 8.8 (m, 1H), 8.65 (m, 
1H ), 8.5 (d, J= 9.6 Hz, 1H ), 8.3 (m, 1H), 8.05 (m, 1H ), 4.7 (m, 
1H), 4.25 (m, 1H), 4.1 (m, 4H), 3.9 (m, 2H), 3.6 (m, 2H), 2.3 (m, 
2H), 1.9-1.8 (m, 5H), 1.6 (m, 4H), 1.4 (m, 4H), 1.0 (m, 6H).  Ir 
(cm
-1
) v  3279 (NH), 2962 (CH), 1641 (C=O), 1529 (NO2).   
LSIMS m/z 628.2 ((M + H)
+
, 43), 650.2 ((M + Na)
+
, 100); 
HRLSIMS: Calc for C26H37N5O11S: 628.2289. Found: 628.222. 
Anal. Calcd for C26H37N5O11S: C, 49.74; H, 5.95; N, 11.16. 
Found: C, 49.56; H, 5.96; N, 10.95. 
4.1.2.4. N-(Methoxycarbonyl)-S-(2,4-dinitrophenyl) 
glutathione di-n-butyl ester (4) was prepared according to 
Method B using methylchloroformate (1.1 eq).  Trituration with 
Et2O gave the expected product as yellow crystals.  Yield 61%; 
mp 124-126C; 
1
H NMR (D6MSO)  8.95 (s, 1H ), 8.7 (m, 1H), 
8.5 (m, 2H), 8.1 (d, J=9.4 Hz,  1H),  7.6 (d, J= 7.0 Hz,   1H), 4.75 
(m, 1H), 4.1 (m, 5H), 3.9 (d, J= 6.8 Hz,  2H), 3.6 (s, 3H),  3.4 (m, 
2H), 2.3 (t, J= 8.1 Hz,  2H), 2.0-1.8 (m, 2H), 1.6 (m, 4H), 1.4 (m, 
4H), 1.0 (t, J= 6.8 Hz, 6H).  Ir (cm
-1
) v 3294 (NH), 2938 (CH),    
1641 (C=O),    1530 (NO2).   LSIMS m/z 644.0 ((M + H)
+
, 100), 
666.0 ((M + Na)
+
, 64);  Anal. Calcd for C26H37N5O12S : C,  48.51; 
H, 5.8; N, 10.89. Found : C, 48.25; H, 5.83; N, 10.89. 
4.1.2.5. N-(Isobutyryl)-S-(2,4-dinitrophenyl)glutathione di-n-
butyl ester (5) was prepared according to Method B using 
isobutyryl chloride.  Purification by PTLC (CHCl3/MeOH : 19/1) 
gave the  product as yellow crystals.  Yield 41%; mp 189-192C; 
1
H NMR (D6MSO)  8.85 (s, 1H), 8.6 (t, J= 5.8 Hz,   1H), 8.4 (d, 
J= 8.6 Hz, 2H), 8.1 (d, J=7.5 Hz, 1H), 7.98 (d, J= 8.6 Hz, 1H), 
4.65 (m, 1H), 4.2 (m, 1H), 4.0 (m, 4H), 3.75 (d, J= 5.7 Hz,    2H), 
3.5 (m, 2H), 2.4 (m, 1H), 2.2 (t, J= 7.9 Hz,  2H), 1.9-1.7 (m, 2H), 
1.5 (m, 4H), 1.3 (m, 4H), 1.0 (d, J=  6.6. Hz, 6H), 0.85 (t, J= 7.5 
Hz, 6H).   Ir (cm
-1
) v  3283 (NH),    2960 (CH), 1642 (C=O),      
1531 (NO2).  LSIMS m/z 656 ((M + H)
+
, 17), 678 ((M + Na)
+
, 
15); HRLSIMS: Calc for C28H42N5O11S: 656.2602. Found: 
656.2582; Anal. Calcd for C28H41N5O11S: C, 51.28; H, 6.31; N, 
10.69. Found:C, 51.04; H, 6.41 ; N, 10.61.  . 
4.1.2.6. N-(Isovaleryl)-S-(2,4-dinitrophenyl)glutathione di-n-
butyl ester (6)  was prepared according to Method B using 
isovaleryl chloride prepared by overnight reflux of  isovaleric 
acid with thionyl chloride.  Purification by PTLC (CHCl3/MeOH; 
19/1) and trituration with Et2O gave the product as yellow 
crystals.  Yield 70%; mp 133-135C; 
1
H NMR (D6MSO)  9.0 (s, 
1H), 8.8 (m, 1H), 8.6 (m, 2H), 8.3 (m,  1H), 8.1 (d, J=9.6 Hz,   
1H), 4.7 (m, 1H), 4.3 (m, 1H), 4.1(m,  4H), 4.0 (m, 2H), 3.6 (m, 
2H),  2.3 (m, 2H), 2.1-1.8 (m, 3H), 1.6 (m, 4H), 1.4 (m, 4H), 1.0 
(m, 12H).  Ir (cm
-1
) v  3280 (NH), 2960 (CH), 1638 (C=O),      
1525 (NO2).   LSIMS m/z 670.3 ((M + H)
+
, 100), 692.3 ((M + 
Na)
+
, 95); Anal. Calcd for C29H43N5O11S, 3H2O: C, 48.12; H, 
6.82; N, 9.68. Found: C, 47.82 ;H, 6.75 ; N, 9.92.   
4.1.2.7. N-(4-Methylvaleryl)-S-(2,4-dinitrophenyl)glutathione 
di-n-butyl ester (7) was prepared according to Method B using 
4-methylvaleryl chloride obtained by overnight reflux  of 4-
methylvaleric acid with thionyl chloride.  Purification by PTLC 
(CHCl3/MeOH : 19/1) and trituration with Et2O gave the product  
as orange  crystals. Yield: 65%; mp 148-150C; 
1
H NMR 
(D6MSO)  9.0 (s, 1H), 8.8 (m, 1H), 8.6 (m, 2H ), 8.3 (m, 1H), 
8.1 (d, J= 9.6 Hz, 1H), 4.7 (m, 1H), 4.3 (m, 4H), 4.1(m,  4H), 4.0 
(m, 2H), 3.6 (m, 2H), 2.3 (m, 2H), 2.2 (m, 2H), 2.0-1.8 (m, 2H), 
1.6 (m, 5H), 1.4 (m, 6H), 1.0 (m, 12H).  Ir (cm
-1
) v  3284 (NH),       
2925 (CH), 1637 (C=O), 1532 (NO2). LSIMS m/z 684.5 ((M + 
H)
+
,100), 706.5 ((M + Na)
+
, 90): Calcd for  
C30H45N5O11S.0.5H2O:  C, 52.04; H, 6.65; N, 10.11. Found: C, 
51.83; H, 6.70 ; N, 9.94.  . 
4.1.2.8. N-(Myristoyl)-S-(2,4-dinitrophenyl)glutathione di-n-
butyl ester (8)) was prepared according to Method B using 
myristoyl chloride. Purification by PTLC (CHCl3/MeOH: 19/1) 
gave the product as a yellow crystals. Yield:  49 %; mp 172-174 
C; 
1
H NMR (D6MSO)  8.85 (d, J= 2.3 Hz, 1H), 8.6 (t, J= 5.7 
Hz,   1H), 8.4 (dd, J= 8.8, 2.3 Hz, 2H), 8.1 (d, J=7.7 Hz, 1H), 
7.98 (d, J= 8.8 Hz, 1H), 4.6 (m, 1H), 4.2 (m, 1H), 4.0 (m, 4H), 
3.85 (d, J= 5.6 Hz, 2H), 3.5 (m, 2H), 2.2 (t, J= 7.6  Hz, 2H), 2.1 
(t, J=7.5 Hz, 2H, 1.9-1.7 (m, 2H), 1.5 (m, 6H), 1.25-1.22 (m, 
24H),  0.8 (t, J= 7.3 Hz, 9H).  Ir (cm
-1
) v 3282 (NH), 2960 (CH),    
1643 (C=O), 1531 (NO2).  LSIMS m/z 796 ((M + H)
+
, 45), 818 
((M + Na)
+
, 58): Anal Calcd for  C38H61N5O11S. H2O: C, 56.07; 
H, 7.80; N, 8.60 . Found: C, 56.18; H, 7.73; N, 8.91.       
4.1.2.9. N-(Benzoyl)-S-(2,4-dinitrophenyl)glutathione di-n-
butyl ester (9) was prepared according to Method B using 
benzoyl chloride.  Trituration with Et2O gave the product as 
yellow crystals.  Yield 72%; mp 144-146C; 
1
H NMR (D6MSO) 
 8.95 (s, 1H ), 8.8 (d, J=8.0 Hz, 1H), 8.7 (m, 1H), 8.5 (m, 2H), 
8.1 (d, J=8.0 Hz,  1H), 7.95 (d, J=8.0 Hz,  2H), 7.55 (m, 3H), 
4.75 (m, 1H), 4.5 (m, 1H),  4.1 (t, J=7.1 Hz,  4H), 3.9 (d, J=7.1. 
Hz,  2H), 3.6 (m, 2H), 2.4 (m, 2H), 2.2-2.0 (m, 2H), 1.6 (m,   
4H), 1.4 (m, 4H), 0.95 (t, J=8.5 Hz,  6H).  Ir (cm
-1
) v  3281 (NH),       
2936 (CH), 1644 (C=O), 1533 (NO2).   LSIMS m/z 690.2 ((M + 
H)
+
, 68), 712.2 ((M + Na)
+
, 32): Anal. Calcd for  C31H39N5O11S: 
C, 53.97 ; H, 5.70; N, 10.16 . Found: C, 54.56; H, 5.42; N, 10.02.       
4.1.2.10. N-(Phenoxyacetyl)-S-(2,4-dinitrophenyl)glutathione 
di-n-butyl ester (10)  was prepared according to Method B using 
phenoxyacetyl chloride (1.1 eq). Purification by PTLC 
(CHCl3/MeOH : 19/1) gave the expected product  as yellow 
crystals.  Yield 66%; mp 98-100C; 
1
H NMR (D6MSO)  8.9 (s, 
1H), 8.8 (m, 1H), 8.7 (t , J=7.9 Hz,  2H), 8.5 (d, J=9.5 Hz,  1H), 
  
8.0 (d, J=9.5 Hz,   1H) , 7.4 (t, J=7.9 Hz,   2H), 7.0 (d, J=7.9 Hz,   
3H), 4.8 (m, 1H), 4.6 (s, 2H),  4.4 (m, 1H), 4.1 (m, 4H), 3.95 (d, 
J=5.5 Hz,  2H), 3.6 (m, 2H), 2.3 (t, J=7.3 Hz,  2H), 2.1-1.95 (m, 
2H), 1.7 (m, 4H), 1.4 (m, 4H), 1.0 (m, 6H).  Ir (cm
-1
) v 3284 
(NH), 2960 (CH), 1643 (C=O), 1531 (NO2).   LSIMS m/z 720.2 
((M + H)
+
, 43), 742.2 ((M + Na)
+
, 27); HRLSIMS: Calc for 
C32H45N4O12S: 737.2816, Found: 737.2811 ; Anal. Calcd for  
C32H41N5O12S: C, 53.39 ; H, 5.75; N, 9.73. Found: C, 53.28; H, 
5.40; N, 9.63.      . 
4.1.2.11. N-(3-Phenylpropionyl)-S-(2,4-dinitrophenyl) 
glutathione di-n-butyl ester (11)  was prepared according to 
Method A using 3-phenylpropionyl chloride. Trituration with 
Et2O gave the product as yellow crystals.  Yield 70%; mp 143-
146C; 
1
H NMR (D6MSO)  9.0 (s, 1H), 8.7 (m, 1H), 8.5 (m, 
2H), 8.4 (d, J= 7.0 Hz, 1H), 8.1 (d, J=8.7 Hz, 1H), 7.4-7.2 (m, 
5H), 4.8 (m, 1H), 4.3 (m, 1H), 4.1(m,  4H), 4.0 (d, J=7.0 Hz,  
2H), 3.6 (m, 2H), 2.9 (t, J= 7.8 Hz, 2H), 2.4 (t, J= 7.0 Hz,  2H), 
2.2 (t, J= 7.8 Hz, 2H), 2.0-1.8 (m, 2H), 1.6 (m, 4H), 1.4 (m, 4H), 
1.0 (m,  6H).  Ir (cm
-1
) v 3294 (NH), 3058 (CH), 1644 (C=O),      
1541 (NO2). HRLISMS calc for C33H43N5O11S 717.2679, Found 
717.2669; Anal. Calcd for C33H43N5O11S: C, 55.21; H, 6.04; N, 
9.76. Found: C, 55.20; H, 6.24; N, 9.83.  . 
4.1.2.12. N-(trans-Cinnamoyl)-S-(2,4-dinitrophenyl) 
glutathione di-n-butyl ester (12) was prepared according to 
Method A using trans-cinnamoyl chloride. Trituration with Et2O 
gave the product as yellow crystals.  Yield 82%; mp 150-155C; 
1
H NMR (D6MSO)  9.0 (s, 1H), 8.7 (m, 1H), 8.6 (m, 3H), 8.1 
(d, J= 9.7 Hz,  1H), 7.6 (d, J= 8.0 Hz,  2H), 7.5 (m, 4H), 6.8 (d, 
J=14.5 Hz, 1H), 4.8 (m, 1H), 4.4 (m, 1H), 4.2 (m, 4H), 4.0 (d, 
2H), 3.6 (m, 2H), 2.3 (t, J=7.0 Hz, 2H), 2.1-1.9 (m, 2H), 1.6 (m, 
4H), 1.4 (m, 4H), 1.0 (m, 6H).  Ir (cm
-1
) v  3241 (NH), 2943   
(CH), 1656 (C=O), 1577 (NO2).   LISMS m/z 716.3 ((M + H)
+
, 
25), 738.3 ((M + Na)
+
, 100); HRLISMS: Calc for C33H42N5O11S: 
716.2601, Found: 716.2593 ; Anal. Calcd for C33H41N5O11S:  C, 
55.37; H, 5.78 ; N, 9.79. Found: C, 55.03; H, 6.04; N, 9.71. 
4.1.2.13. N-(Benzyloxycarbonyl)-S-(2,4-dinitrophenyl) 
glutathione di-n-butyl ester (13) was prepared according to the 
previously described procedure
24
. 
4.1.2.14. N-(Indolepropionyl)-S-(2,4-dinitrophenyl) 
glutathione di-n-butyl ester (14) was prepared according to the 
method described by Cabre et al
 58  
using indolepropionic acid 
(1eq), N,N-bis[2-oxo-3-oxazolidinyl]phosphonic chloride (BOP-
Cl) (1eq) as activator, Et3N (1eq) and 2 (1eq) in a 
dichloromethane solution (~20ml). Purification by PTLC 
(CHCl3/MeOH : 9 / 1) gave the product as orange crystals.  Yield 
62%; mp 145-150C;  
1
H NMR (D6MSO)  10.9 (m, 1H), 9.0 (s, 
1H), 8.8 (m, 1H), 8.7 (d, J= 9.0 Hz, 1H), 8.5 (d, 9.0 Hz, 1H), 8.4 
(d, 9.0 Hz, 1H), 8.1 (d, 9.0 Hz, 1H), 7.6 (d, 9.0 Hz,  1H), 7.4 (d, 
9.0 Hz, 1H), 7.0-7.2 (m, 3H), 4.7 (m, 1H), 4.3 (m, 1H), 4.1(m, 
4H), 4.0 (m, 2H), 3.6 (m, 2H), 3.0 (m, 2H), 2.3 (m, 2H), 2.0-1.8 
(m, 2H), 1.6 (m, 6H), 1.4 (m, 4H), 1.0 (m, 12H).  Ir (cm
-1
) v     
3285 (NH),       2958 (CH), 1643 (C=O), 1531 (NO2).   ESIMS 
m/z 757 ((M + H)
+
, 20), 779 ((M + Na)
+
, 100), 755 ((M - H)
-
, 80), 
791 ((M + Cl)
-
, 85); Anal. Calcd for C35H44N6O11S.4H2O: C, 
50.72; H, 5.32; N, 10.14. Found: C, 50.69; H, 5.26; N, 10.32.  . 
4.1.2.15. N-(Trimethylacetyl)-S-(2,4-dinitrophenyl) 
glutathione di-n-butyl ester (15) was prepared according to 
Method B using trimethylacetyl chloride (1.1eq). Trituration with 
Et2O/ pet ether (40-60) gave the product as yellow crystals. Yield 
50%; mp 88-90C; 
1
H NMR (D6MSO)  8.9 (s, 1H), 8.6 (t, J=5.6 
Hz, 1H), 8.5 (d, J= 7.9 Hz, 2H), 8.0 (d, J= 9.0 Hz, 1H), 7.75 (d, 
J= 7.9 Hz, 1H), 4.65 (m, 1H), 4.2 (m, 1H),  4.0 (m, 4H), 3.95 (d, 
J=5.1 Hz, 2H), 3.6 (m, 2H), 2.3 (m, 2H), 2.0-1.8 (m, 2H), 1.5 (m, 
4H), 1.3 (m, 4H), 1.1 (m, 9H), 0.85 (t, J= 7.4 Hz, 6H).  Ir (cm
-1
) v     
3285 (NH), 2918 (CH), 1642 (C=O), 1521 (NO2).   CIMS m/z 
670.6 ((M + H)
+
, 100), 687.6 ((M + NH4)
+
, 15) ; Anal. Calcd for 
C29H43N5O11S: C, 52.00; H, 6.48; N, 10.46. Found: C, 51.99; H, 
6.52; N, 10.37.   
4.1.2.16. N-(tert-Butoxycarbonyl)-S-(2,4-dinitrophenyl) 
glutathione di-n-butyl ester (16) was prepared according to 
Method B using di-tert-butyl dicarbonate (1eq).  Purification by 
PTLC (CHCl3/MeOH : 9/1) gave the expected product as yellow 
crystals.  Yield 51%; mp 108-110C; 
1
H NMR (D6MSO)  9.0 (s, 
1H), 8.8 (m, 1H), 8.5 (m, 2H), 8.1 (d, J=8.7 Hz, 1H), 7.4 (d, 
J=8.7 Hz,  1H), 4.8 (m, 1H), 4.2-3.9 (m, 7H), 3.6 (m, 2H), 2.3 
(m, 2H), 2.0-1.8 (m, 2H), 1.6 (t, J=7.8 Hz, 4H), 1.4 (m, 13H), 1.0 
(t, J=7.8 Hz,   6H).  Ir (cm
-1
) v  3285 (NH), 2918 (CH), 1642  
(C=O), 1521 (NO2).  LSIMS m/z 686.3 ((M + H)
+
, 100), 708.3 
((M + Na)
+
, 85) ; Anal. Calcd for C29H43N5O12S:  C, 50.78; H, 
6.32 ; N, 10.22. Found: C, 50.40; H, 6.28  ; N, 9.82.    
4.1.2.17. N-(tert-Butylacetyl)-S-(2,4-dinitrophenyl)glutathione 
di-n-butyl ester (17) was prepared according to Method B using 
tert-butylacetyl chloride. Purification by PTLC (CHCl3/MeOH : 
9/1) gave the product as yellow crystals.  Yield 45%; mp 118-
120C; 
1
H NMR (D6MSO)  9.0 (s, 1H), 8.8 (m, 1H), 8.5 (m, 
2H), 8.2 (d, J=8.7 Hz,  1H), 8.1 (d, J=9.6 Hz,  1H), 4.8 (m, 1H), 
4.3 (m, HN-CH-CH2), 4.1 (m, 4H), 4.0 (d, J=7.0 Hz, 2H), 3.6 (m, 
2H), 2.3 (m, 2H), 2.2 (s, 2H), 2.0-1.8 (m, 2H), 1.6 (t, 4H), 1.4 (m, 
13H), 1.0 (t, 6H).  Ir (cm
-1
) v 3280 (NH), 2959 (CH), 1642 
(C=O), 1531 (NO2). HRLSIMS: Calc for C30H45N5O11S: 
683.2836. Found  683.2841; Anal. Calcd for C30H45N5O11S: C, 
52.70; H, 6.63; N, 10.24. Found: C, 52.41; H, 7.23,  N; 10.34. 
4.1.2.18. N-(Adamantyloxycarbonyl)-S-(2,4-dinitrophenyl) 
glutathione di-n-butyl ester (18) was prepared according to 
Method B using 1-adamantyl fluoroformate (1eq x 3). 
Purification by PTLC (CHCl3/AcOH : 25/1) gave the product as 
yellow crystals.  Yield 51%; mp 72-74C; 
1
H NMR (D6MSO)  
9.0 (s, 1H), 8.75 (m, 1H), 8.5 (d, J=  8.1  Hz, 2H), 8.05 (d, J=8.7 
Hz,  1H), 7.35 (d, J=8.1 Hz,  1H), 4.75 (m, 1H), 4.15 (t, J= . Hz, 
4H), 3.9 (d, J= 5.9 Hz,  3H), 3.6 (dd, J= 14.4, 5.9 Hz,   2H), 2.3 
(bs, 3H), 2.1 (s, 2H), 2.0 (bs, 8H), 1.65 (bs, 10H), 1.4 (m, 4H), 
0.95 (t, J= 8.0 Hz,  6H).  Ir (cm
-1
) v 3284 (NH), 2912 (CH),    
1641 (C=O), 1514 (NO2).   Anal. Calcd for C35H49N5O11S. 0.5 
H2O: C, 54.43; H, 6.47; N, 9.06. Found: C, 54.39; H, 6.43  ; N, 
9.1. 
4.1.2.19. N,S-(2,4-Dinitrophenyl)glutathione di-n-butyl ester 
(19) was prepared by thionyl chloride esterification of  N, S-(2,4-
dinitrophenyl)glutathione
24
 in butanol (Method A). Trituration 
with Et2O gave the  product as yellow crystals.  Yield 85%; mp 
130-135C; 
1
H NMR (D6MSO)  9.0 (m, 3H), 8.7 (t, J= 6.7 Hz, 
1H), 8.6 (d, J= 8.3 Hz, 1H), 8.5 (m, 1H), 8.3 (m, 1H), 8.0 (d, J= 
8.3 Hz, 1H), 7.2 (d, J= 8.3 Hz,  1H), 5.0 (m, 1H), 4.8 (m, 1H),  
4.2 (m, 2H), 4.1 (m, 2H),  3.9 (t, J= 6.7 Hz,  2H), 3.6 (m, 2H), 
2.3-2.2 (m, 4H), 1.7 (m, 4H), 1.4 (m, 4H), 1.0 (m, 6H).  Ir (cm
-1
) 
v 3283 (NH), 2959 (CH), 1642 (C=O), 1526 (NO2).   LSIMS m/z 
752.3 ((M + H)
+
, 67), 774.2 ((M + Na)
+
, 70); Anal. Calcd for 
C30H37N7O14S.H2O: C, 46.80; H, 5.11; N, 12.74. Found: C, 47.24; 
H, 4.89; N, 12.77.   
4.1.2.20. N-(4-amino-6-chloro-1,3,5-triazin-2-yl)-S-(2,4-
dinitrophenyl)glutathione di-n-butyl ester  (20)  was prepared 
according to  Method B using cyanuric chloride and CH3CN 
replacing MeOH as the reaction solvent.  After reaction for 4hr a 
saturated solution of ammonia in MeOH (20 ml) was added to 
the reaction and the solution stirred for a further 1 hr.  The 
solution was then evaporated and the residue dissolved in AcOEt 
and filtered to remove insoluble material.  The organic layer was 
  
washed with HCl, water, dried MgSO4, filtered and evaporated to 
give a solid.  Purification by PTLC (CHCl3/EtOH : 9/1) gave the 
expected product as pale yellow crystals.  Yield 16.8 %; mp 86-
90C; 
1
H NMR (D6MSO)  8.8(s, 1H), 8.3 (dd, J=8.7, 2.9  Hz, 
1H), 7.4 (d, J=7.2 Hz, 1H), 7.3-7.1 (m, 3H), 6.4 (d, J= 8.5 Hz, 
1H),   5.8 (bs, 2H), 4.8 (m, 1H), 4.6 (m, 1H), 4.1 (t, J=7.1 Hz,   
4H), 4.0 (m, 2H), 3.4 (m, 2H), 2.4 (m, 2H), 2.3-2.0 (m, 2H), 1.6 
(m,   4H), 1.4 (m, 4H), 0.9 (t, J=7.7 Hz,  6H).  Ir (cm
-1
) v  3286 
(NH), 2961 (CH), 1642 (C=O),  1530 (NO2).   LSIMS m/z 741.1 
((M + H)
+
, 18), 763.1 ((M + Na)
+
, 54); HRLSIMS: calc for 
C30H41N8O10-SCl: 741.2433. Found  741.2431; Anal. Calcd for 
C30H40N8O10SCl: C, 48.63; H, 5.58; N, 15.13. Found: C, 48.61; 
H, 6.10; N, 14.89.   
4.2. Biological Procedures 
4.2.1. Quantitative Structure Activity Regression (QSAR).  
Initial studies were undertaken using the SciQSAR  module of 
Alchemy 2000 (Tripos) running under Win 98 for data analysis 
as previously reported.
26
  However in the absence of a simple 
graphical relationship between the experimental and calculated 
parameters and the large size of the data set used this led us to 
use the CODESSA Pro program for statistical analysis.  This 
program uses diverse statistical structure property/activity 
correlation techniques for the analysis of experimental data in 
combination with independently calculated molecular 
descriptors.  The program is an advanced fully featured QSAR 
program for analysis of experimental  data sets, commercially 
available (SemiChem, Inc), which was  provided to us in 2004 by 
Professor Katritzky, of the Univ of Florida during its evaluation 
and to whom we are indebted.  Structures inputted into the 
program were constructed using Alchemy 2000, optimized and 
saved to file in the mdl.mol format.  A text input file was created, 
excluding tabs, containing compound names, mol file path, one 
property (log ED50) and one extra descriptor(log P) for each of 
the 19 di-ester compounds 2-19.   The data file was loaded into 
the Codessa Pro program and used to calculate constitutional, 
topological, geometrical and electrostatic descriptors totaling 166 
for each compound.  The large number of descriptors was filtered 
using the program’s heuristic method which was used to 
determine a multi-linear regression QSAR relationship assuming 
zero for missing descriptors and the constraint of three or less 
descriptors. The heuristic method (HM)
39
 was implemented in 
Codessa Pro to select the ‘best’ regression models.   It quickly 
gives an estimation as to the quality of correlation to expect from 
the data, and derives several best regression models excluding 
descriptors that have bad or missing values, descriptors that are 
insignificant, and descriptors which are highly inter-correlated.  
This information is then used to reduce the number of descriptors 
involved in identifying the best QSAR model.   The goodness of  
the fit of each correlation was tested by the regression 
coefficient(R2), where  a value close to 1.0 represents the better 
fit to the model.  The F-test the Fisher ratio of the variance 
explained by the model and the variance due to the error in the 
model (i.e., not explained by the model), where high values of  F 
indicate that the model is statistically  significant.  The standard 
error shown by the squared cross-validated coefficient (s
2
), 
expresses the variation of the residuals or the variation about the 
regression line and measures the model error.  If the model is 
correct, it is an estimate of the error of the data variance.  The t-
test measures the statistical significance of the regression 
coefficients, high t-test values correspond to the relatively more 
significant regression coefficients.  The confidence limits of the 
regression coefficient (DX), are also reported.  The model, which 
passed the above statistical diagnosis with as few descriptors as 
possible was chosen.  The regression analysis was further 
improved by diagnosis during the  stepwise removal  of outliers 
from the data set in whilst examining  its effect  not to  
significantly  enhance the statistics of the model.  When the 
optimum QSAR set was achieved for the identified  descriptors 
the  QSAR model was constructed on the basis of the reduced 
dataset.  
The molecular property descriptor, log P (log KOW) , was 
included in the descriptor set and was  calculated for each of the 
individual molecules using the desktop version of this program 
EPE  suite program obtained from  the Environmental Service 
Centre, Syracuse Research Corporation
59
   running under WinXP.   
The program uses the atom/fragment contribution method to 
estimate the log octanol-water partition coefficient, log KOW of 
compounds.   This method  uses a dataset from full compounds, 
or fragments, that are experimentally determined, and then 
modelled using QSPR or other regression techniques into small 
fragments  than per atom. Fragment contributions are then added 
up, with correction factors.  Log KOW  values are calculated by the 
program by importing MDL mol structures of molecules  
constructed using Alchemy 2000 with the exception of 
compound 18 where due to large number of atoms,  the program, 
xlog P 
60  
was used. 
4.2.2.  General Methods 
Parasites: Trypanosoma brucei rhodesiense (STIB900) 
bloodstream form trypomastigotes were maintained in HMI-18 
medium
 61,62
 with 20% heat inactivated foetal calf serum (HIFCS) 
(Harlan Sera-Lab., Crawley, UK) at 37
o
C in 5% CO2-air mixture.  
Leishmania donovani (strain MHOM/ET/67/HU3) was 
maintained routinely in special pathogen free (SPF) female 
Golden hamsters by serial passage every 6 to 8 weeks.  
Trypanosoma cruzi (strain MHOM/BR/OO/Y) trypomastigotes 
were derived from MDCK fibroblasts in Dulbecco’s Modified 
Eagle medium (Life Technologies Ltd., Paisley, Scotland) with 
10% HICFS at 37
o
C in a 5% CO2-air mixture.  
4.2.3. Evaluation of the parasitic activity of glutathione 
derivatives in vitro 
4.2.3.1. T. brucei rhodesiense: All compounds were tested in 
triplicate in a three-fold dilution series from a top concentration 
of 30 M.  Parasites were diluted to 2x10
5
/mL and added in 
equal volumes to the test compounds in 96-well, flat bottom 
Microtest III
TM
 tissue culture plates (Becton Dickinson and 
Company, NJ, USA).  Appropriate controls with pentamidine 
isethionate (Sanofi, UK) as the positive, were set up in parallel.  
Plates were maintained for 3 days at 37
o
C in a 5% CO2-air 
mixture as pentamidine is known to be efficacious in this time 
frame and  the ultimate aim is to match or improve upon its  
potency.  Compound activity was determined on day three by the 
use of the Alamar Blue assay.
63 
4.2.3.2.  L. donovani and T. cruzi.  Peritoneal macrophages were 
harvested from female CD1 Mice (Charles Rivers Ltd., Margate, 
UK) by peritoneal lavage 24 h after starch (Merck Ltd., Leics, 
UK) induced recruitment.  After washing cells were dispensed 
into 16-well Lab-tek
TM
  tissue culture slides (Nunc Inc., IL, USA) 
at 4x10
4
/well in a volume of 100 mL of RPMI-1640 medium 
(Sigma-Aldrich Company Ltd., Dorset, UK) and 10% HIFCS. 
After 24h, macrophages were infected at a ratio of 10:1 
(4x10
5
/well) with L. donovani amastigotes or 5:1 (2x10
5
/well) 
with T. cruzi  trypomastigotes.  Infected macrophages were then 
maintained in the presence of drug in a three-fold dilution series 
in quadruplicate for 5 days in the case of L. donovani and 3 days 
with T. cruzi, the standard time frame taken for the respective 
control drugs to work.  Drug activity was evaluated from the 
percentages of macrophages cleared of amastigotes in treated 
  
cultures.  Sodium stibogluconate (NaSb
v
) (GSK, UK) and 
benznidazole (Bayer, UK) were used as the respective controls
 
.
64 
4.2.4. Evaluation of the cytotoxicity of glutathione derivatives 
in-vitro. 
Cytotoxicity testing on KB cells (human oral pharyngeal 
carcinoma) was evaluated using a one step fluorometric assay.
65
  
Cell cultures were grown in RPMI medium with 10% calf foetal 
serum (CFS) at 37
o
C in a 5% CO2-air mixture in a humidified 
incubator.  Plates were incubated with compound for 3 days at 
37
o
C in a 5% CO2-humidified air mixture prior to determination 
of activity. 
4.2.5. Membrane location studies by HPLC-UV. 
T. b. brucei S247 cells (1 x 10
6
 cells/ml; bloodstream form)  
grown in HMI-9 medium were incubated in the same media with 
10% calf foetal serum (CFS) at 37
o
C for 3h with N-
benzyloxycarbonyl-S-(4-bromobenzyl)glutathione dimethyl ester 
(50 M) in 1% DMSO (ED50 ~30 M 
14
).  Aliquots (1 ml) were 
taken at the start of the reaction and time intervals 5, 60 and 120 
mins and  sedimented by centrifugation (2 mins; 7000 rpm) and 
the supernatant removed. Trichloroacetic acid (TCA)(20l) was 
then added to the supernatant (~1ml) and the sample analysed by 
HPLC-UV (extracellular). The sedimented cell pellet was washed 
with PBS (1ml) and centrifuged (2 mins; 7000 rpm). The cell 
pellet was re-suspended in HMI-9 media (1ml), TCA (20l),  
lysed  and  then centrifuged (13,000 rpm, 10mins) and the 
supernatant removed  and stored at -20°C for HPLC analysis 
(intracellular). The metabolites of N-benzyloxycarbonyl-S-(4-
bromobenzyl)glutathione dimethyl ester, N-benzyloxycarbonyl-
S-(4-bromobenzyl)glutathione monomethyl ester and N-
benzyloxycarbonyl-S-(4-bromobenzyl)glutathione, formed in the 
extracellular or intracellular medium of T.b.brucei cells in culture 
were analysed in triplicate by reversed-phase HPLC-UV.   A 
control was run without inhibitor to ascertain that 1 % DMSO 
had no effects on the activity of parasites.   Analysis was 
undertaken on a Hewlett Packard series 1100 HPLC system using 
a Techsphere ODS (25cm x 4.6mm) column eluted with a 
mobile phase of CH3CN/H2O (1:1), TFA (50mM) at a flow rate 
of 2ml/min, OD 235nm. The retention times of N-
benzyloxycarbonyl-S-(4-bromobenzyl)glutathione dimethyl 
ester, N-benzyloxycarbonyl-S-(4-bromobenzyl)glutathione 
monomethyl ester and N-benzyloxycarbonyl-S-(4-bromobenzyl) 
glutathione (mean ( SD), n = 16) were 6.3 ( 0.2), 3.9 ( 0.5) 
and 2.3 ( 0.2) mins respectively. Calibration curves were 
produced for analysis of N-benzyloxycarbonyl-S-(4-
bromobenzyl) glutathione dimethyl ester and N-
benzyloxycarbonyl-S-(4-bromobenzyl)glutathione
24
  over a range 
of concentrations of 0.5-500M and 0.5-100M respectively.  
The concentration ranges were limited due to solubility problems 
and the detection limit of these compounds by HPLC-UV of 
<0.5M.   Analysis of diester breakdown products were 
undertaken as above for the analysis of the intracellular contents 
of parasitic cells where the HMI-9 media (1ml) was replaced 
either with 1M NaCl or 6M urea. 
4.2.6. Optical Microscopy 
Morphological changes induced by S-bromobenzylglutathione 
dimethyl ester (SBrBzGSMe2) 
24
 were investigated by incubation 
of T. b. brucei cells (1 x 10
6
/mL; 1 x 10
6
) for 1hr in the presence 
of 50 M (SBrBzGSHMe2).  A sample of the treated solution 
was monitored by optical microscopy using a Leitz Aristoplan 
microscope, X40 PL fluorotar objective with Nomarski 
interference illumination.  Photographs of the parasites were 
taken over a 1hr period on Fuji sensia 100 film using a Nikon 
801 and Nikon SB25 flash on a TTL cord  to freeze the motion. 
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Compound 
ID 
ED50 (M)
d 
ED50 (M)
c,e
 ED50 (M)
c, f 
ED50 (M) Relative Tox 
 Log P
a
 
G 
T. b. rhodesiense L. donovani T. cruzi KB cells
b 
KB/T.b.rhod kJ mol
-1 
1 >30 >30 >30     
2 1.88 19.9/t t/+ 107.4 57.1 2.25 0.0 
3 6.52 NA 37.8 >300 >46 2.7 -3.1 
4 2.15 >30(5.4) 30.4 >300 >139 3.35 -0.3 
5 0.73 NA 30.8 >300 >411 3.61 2.3 
6 1.16 >30(4.6) >30(35.6) 59.6 51.4 4.1 1.2 
7 1.02 NA NA 84 82.3 4.59 1.5 
8 32.6 NA >30 >300 >9.2 8.73
a
 -7.1 
9 0.55 NA 22.9 >300 >545 4.1 3.05 
10 0.6 NA >30 >300 >500 4.43 2.8 
11 2.02  >30(18.4) >30(29.7) >300 >148 4.9 -0.2 
12 0.28  NA >30(33.4) 34.4 123 4.68 4.7 
13 0.42  >30 (36) NA 95.2 227 5.06 3.7 
14 0.30   NA 35.01 26 87 3.45 4.55 
15 0.6 NA 8.4 83.4 139 4.06 2.8 
16 0.22  9.9 2.9 16.5 70.4 320 4.71 5.3 
17 4.38   NA 12.04 250.2 57.1 4.55 -2.1 
18 0.5 10.06 4.5 >300 >600 6.74
a
 3.3 
19 0.72  NA NA >300 >417 4.73 2.4 
20 18.8 NA  NA  >300 >15.9 3.27 -5.7 
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 Antiparasitic glutathione derivatives 
 Inhibitors of Trypanosomiasis rhodesiense 
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 Inhibitors targeting the flagellar membrane pocket 
 
 
